Recent Updates
Recently added Catalysts
ELDN Positive Sentiment Score: 70/100

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Thursday, March 23, 2023 2 min read
Key Takeaway: Eledon Pharmaceuticals has announced that it will release its financial results for the fourth quarter and full year of 2022 on March 30, 2023. Following the results, the company will host a conference call and webcast to discuss the findings with investors. Eledon is focused on developing treatments targeting the CD40 Ligand pathway, with its lead compound being tegoprubart for various serious medical conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is preparing to report its financial results, indicating ongoing business activities.
  • The management team is engaging with investors through a conference call and webcast, promoting transparency.
  • Eledon's focus on developing potential treatments for serious health conditions showcases its commitment to medical innovation.

Full Press Release Details

IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 30, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Conference Call and Webcast Details:
Thursday, March 30, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-300-8521
International: 412-317-6026
Conference ID: 10175955
Webcast: https://ir.eledon.com/events-and-presentations/events
After the live webcast, the event will be archived on Eledon’s website for one year.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
stephen@gilmartinir.com
Source: Eledon Pharmaceuticals

Tags

Frequently Asked Questions

When will Eledon Pharmaceuticals report its financial results?

Eledon will announce its financial results on March 30, 2023.

What time is Eledon's conference call on March 30?

The conference call is scheduled for 4:30 p.m. ET on March 30.

How can I access Eledon's financial results webcast?

The webcast can be accessed at Eledon's events page: ir.eledon.com.

What is Eledon's main drug candidate?

Eledon's lead drug candidate is tegoprubart, an anti-CD40L antibody.

What diseases is Eledon targeting with its treatments?

Eledon focuses on organ transplants, autoimmune diseases, and ALS.

Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals tegoprubart financial results quarterly report biotechnology
Last updated: Mar 23, 2023